Experience of using brentuximab vedotin in combination with chemotherapy for stage IV Hodgkin lymphoma in Ukraine
Kryachok I.A.1, Titorenko I.B.1, Moroz Yu.V.1, Aleksyk O.M.1, Kadnikova T.V.1, Pastushenko Ya.V.1, Rudyuk T.O.1, Burtna A.S.1, Shokun N.V.1, Khodak V.P.2, Nazar R.Ya.3, Karnabeda O.A.4, Myhalska L.V.5, Krutoguz A.S.6, Prokhach A.V.7
- 1State Non-Profit Enterprise «National Cancer Institute», Kyiv, Ukraine
- 2State Institution «Institute of Medical Radiology and Oncology named after S.P. Grigoriev National Academy of Medical Sciences of Ukraine», Kharkiv, Ukraine
- 3State Non-Profit Enterprise «Lviv Territorial Medical Association «Clinical Hospital for Scheduled Treatment, Rehabilitation and Palliative Care», Ukraine
- 4Oncology Clinic «Innovation», v. Lyutizh, Ukraine
- 5Feofaniya Clinical Hospital, Kyiv, Ukraine
- 6Municipal Enterprise «Dnipro Regional Clinical Oncology Dispensary», Ukraine
- 7Dnipro State Medical University, Ukraine
Summary. Stage IV Hodgkin lymphoma (HL) remains a significant therapeutic challenge, especially in patients with poor prognostic factors. The incorporation of targeted agents, such as brentuximab vedotin, in first-line treatment regimens opens up new opportunities to improve clinical outcomes. The aim of the study was to evaluate the efficacy and safety of brentuximab vedotin in combination with chemotherapy according to the A + AVD regimen in patients with stage IV HL in Ukraine. Тhe use of brentuximab vedotin in the A + AVD regimen in patients with stage IV HL demonstrates encouraging results in real clinical practice in Ukraine and is a promising direction in the treatment of advanced-stage HL.
Leave a comment